NexGel (NXGL)
Manufactures customizable hydrogels and sells consumer, white-label, and licensed surgical biomaterials.
Something off on this page? Send us feedback.
Manufactures electron-beam cross-linked hydrogel materials and finished products for contract customers, consumer brands, and white-label partners, while its BioNX Surgical division markets licensed biomaterials for wound care, soft-tissue repair, and orthopedics.
Combines Langhorne, Pennsylvania hydrogel manufacturing and consumer brands with a Texas joint venture that converts and packages finished goods. Contract Manufacturing supplies hydrogel roll stock for therapeutic patches, wound and burn dressings, medical-device components, and cosmetics; Custom and White Label develops infused gels and finished units for customer brands. Consumer Branded Products include MedaGel, Kenkoderm, and Silly George, sold through e-commerce, Amazon, retail partners, and specialized medical offices.
Uses electron-beam cross-linking to tailor adherence, absorption, thickness, and active-ingredient release. BioNX Surgical adds licensed placental-derived biomaterials for wound care, soft-tissue repair, and orthopedics. The Langhorne facility operates under FDA and cGMP requirements, while BioNX manufacturing rights are governed separately and its commercialization uses outside manufacturing partners.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $492.0K · Total debt $7.5M · Total assets $26.4M · Shareholders' equity $4.9M
- Revenue
- $3.7M
- Operating income
- −$2.5M
- Net income
- −$3.6M
No dividends on record.
| Institutions | 6.94% | 587.9K shares | |
|---|---|---|---|
| 18 holders · as of Jun 30, 2026 | |||
| Insiders | 15.00% | 1.27M shares | |
| 8 holders · as of Jun 23, 2026 | |||
| Other | 78.06% | 6.62M shares | |
| remainder | |||
8.48M company shares as of Sep 12, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (9.75M in the company's Sep 23, 2026 report, 8.48M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Asymmetry Point LPInstitution | 8.79% | 745,000 | filed Apr 29, 2026 |
John Nachum SteinInsiderdirector | 5.56% | 471,456 | filed Nov 22, 2024 |
Adam R. LevyInsiderdirector, officer: Chief Executive Officer | 3.81% | 322,692 | filed Jun 23, 2026 |
steven mark glassmanInsiderdirector | 1.85% | 156,655 | filed Feb 12, 2025 |
Scott Robert HenryInsiderdirector | 1.34% | 113,356 | filed Oct 6, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 23, 2026 | Adam R. Levy | director, officer: Chief Executive Officer | −5,000 | $0.5933 |
| Jun 18, 2026 | Adam R. Levy | director, officer: Chief Executive Officer | −6,000 | $0.5921 |
| Jun 11, 2026 | Adam R. Levy | director, officer: Chief Executive Officer | −3,000 | $0.6136 |
| Jun 8, 2026 | Adam R. Levy | director, officer: Chief Executive Officer | −3,000 | $0.5470 |
| Jun 4, 2026 | Adam R. Levy | director, officer: Chief Executive Officer | −3,000 | $0.5936 |
- Solventum
Direct benchmark in surgical drapes and advanced wound dressings.
- MiMedx
Placental allograft leader in wound care and surgical recovery.
- Organogenesis
Broad placental-allograft portfolio across wound and surgical care.
- OR Royalties
Psoriasis-focused skincare overlap through CeraVe topical care.
- Kenvue
Consumer wound care and blemish patches under BAND-AID.
- Johnson & Johnson
Surgical wound-closure platforms overlap with fragile-skin devices.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NexGel | $0.2656 | −3.37% | $2.3M | — | — | 0.2 | +27.8% |
| Solventum | $88.61 | −0.16% | $15.37B | 10.8 | 13.0 | 1.8 | +2.2% |
| MiMedx | $4.72 | −4.36% | $718.6M | 123.2 | 47.5 | 2.0 | −34.7% |
| Organogenesis | $1.44 | −2.84% | $190.4M | — | — | 0.4 | −56.7% |
| OR Royalties | $36.22 | −3.54% | $7.04B | 25.0 | 22.2 | 19.4 | +62.1% |
| Kenvue | $17.70 | −0.90% | $34.29B | 20.5 | 14.8 | 2.2 | +3.0% |
| Johnson & Johnson | $268.29 | −0.33% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Median | 25.0 | 22.2 | 2.1 | +2.6% |